A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients With Select Autoimmune Rheumatic Diseases
Latest Information Update: 12 Dec 2024
Price :
$35 *
At a glance
- Drugs DR-0201 (Primary)
- Indications Cutaneous lupus erythematosus; Dermatomyositis; Polymyositis; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Dren Bio
- 10 Dec 2024 Planned End Date changed from 1 Nov 2026 to 1 Dec 2026.
- 10 Dec 2024 Planned primary completion date changed from 1 Nov 2026 to 1 Dec 2026.
- 10 Dec 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Nov 2024 to 1 Dec 2024.